Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

We are witnessing a long-awaited transformation in depression care. After decades of incremental change, new therapeutic ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease ...

At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type ...

With the ink barely dry on one takeover agreement, Novartis has signed another, promising to pay up to $2 billion to acquire ...

"Screening is typically recommended for patients with confirmed liver cirrhosis or severe liver disease, since many cases of ...

Almost four months ahead of schedule, Corcept Therapeutics' selective glucocorticoid receptor antagonist (SGRA) relacorilant ...

The data reveal from the phase 1 INLIGHT study of WVE-007 – an oligonucleotide-based gene-silencing drug designed to switch ...

Every clinical trial is built on the promise that the risk is justified by the strength of the evidence supporting it.

Novo Nordisk has reported the first mid-stage clinical data with its triple G agonist for diabetes in China, as it starts an ...

What is less often examined is how healthcare professionals actually experience survey design, and where common research ...

Denali Therapeutics' Avlayah is the first drug for neurological complications associated with the rare lysosomal storage ...